vs
Side-by-side financial comparison of Akebia Therapeutics, Inc. (AKBA) and AMERISAFE INC (AMSF). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $57.6M, roughly 1.4× Akebia Therapeutics, Inc.). On growth, Akebia Therapeutics, Inc. posted the faster year-over-year revenue change (23.9% vs 10.3%). Over the past eight quarters, Akebia Therapeutics, Inc.'s revenue compounded faster (32.9% CAGR vs 2.8%).
Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
AKBA vs AMSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $57.6M | $80.1M |
| Net Profit | — | $8.1M |
| Gross Margin | 78.2% | — |
| Operating Margin | -14.8% | — |
| Net Margin | — | 10.2% |
| Revenue YoY | 23.9% | 10.3% |
| Net Profit YoY | — | -9.0% |
| EPS (diluted) | $-0.05 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $80.1M | ||
| Q4 25 | $57.6M | $81.6M | ||
| Q3 25 | $58.8M | $82.0M | ||
| Q2 25 | $62.5M | $81.1M | ||
| Q1 25 | $57.3M | $72.6M | ||
| Q4 24 | $46.5M | $74.0M | ||
| Q3 24 | $37.4M | $78.7M | ||
| Q2 24 | $43.6M | $75.8M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | — | $10.4M | ||
| Q3 25 | $540.0K | $13.8M | ||
| Q2 25 | $247.0K | $14.0M | ||
| Q1 25 | $6.1M | $8.9M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-20.0M | $14.3M | ||
| Q2 24 | $-8.6M | $11.0M |
| Q1 26 | — | — | ||
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | -14.8% | 15.6% | ||
| Q3 25 | 7.6% | 21.3% | ||
| Q2 25 | 22.6% | 21.5% | ||
| Q1 25 | 23.6% | 15.5% | ||
| Q4 24 | -30.8% | 22.7% | ||
| Q3 24 | -33.4% | 22.6% | ||
| Q2 24 | -20.0% | 18.1% |
| Q1 26 | — | 10.2% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 0.9% | 16.9% | ||
| Q2 25 | 0.4% | 17.2% | ||
| Q1 25 | 10.7% | 12.3% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | -53.5% | 18.2% | ||
| Q2 24 | -19.7% | 14.5% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $-0.05 | $0.55 | ||
| Q3 25 | $0.00 | $0.72 | ||
| Q2 25 | $0.00 | $0.73 | ||
| Q1 25 | $0.03 | $0.47 | ||
| Q4 24 | $-0.10 | $0.69 | ||
| Q3 24 | $-0.10 | $0.75 | ||
| Q2 24 | $-0.04 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.8M | $34.2M |
| Total DebtLower is stronger | $48.3M | — |
| Stockholders' EquityBook value | $32.6M | $246.6M |
| Total Assets | $376.6M | — |
| Debt / EquityLower = less leverage | 1.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $34.2M | ||
| Q4 25 | $184.8M | $61.9M | ||
| Q3 25 | $166.4M | $54.7M | ||
| Q2 25 | $137.3M | $48.5M | ||
| Q1 25 | $113.4M | $44.8M | ||
| Q4 24 | $51.9M | $44.1M | ||
| Q3 24 | $34.0M | $63.7M | ||
| Q2 24 | $39.5M | $30.6M |
| Q1 26 | — | — | ||
| Q4 25 | $48.3M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $47.1M | — | ||
| Q1 25 | $46.5M | — | ||
| Q4 24 | $38.7M | — | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $38.0M | — |
| Q1 26 | — | $246.6M | ||
| Q4 25 | $32.6M | $251.6M | ||
| Q3 25 | $41.6M | $274.8M | ||
| Q2 25 | $29.2M | $265.6M | ||
| Q1 25 | $24.6M | $260.8M | ||
| Q4 24 | $-49.2M | $257.3M | ||
| Q3 24 | $-50.4M | $314.4M | ||
| Q2 24 | $-33.8M | $301.0M |
| Q1 26 | — | — | ||
| Q4 25 | $376.6M | $1.1B | ||
| Q3 25 | $364.2M | $1.2B | ||
| Q2 25 | $345.6M | $1.2B | ||
| Q1 25 | $310.2M | $1.2B | ||
| Q4 24 | $220.7M | $1.2B | ||
| Q3 24 | $207.1M | $1.3B | ||
| Q2 24 | $220.2M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.61× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.1M | — |
| Free Cash FlowOCF − Capex | $31.1M | — |
| FCF MarginFCF / Revenue | 53.9% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $67.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $31.1M | $11.1M | ||
| Q3 25 | $28.1M | $10.7M | ||
| Q2 25 | $22.3M | $-8.4M | ||
| Q1 25 | $-13.6M | $-1.8M | ||
| Q4 24 | $-4.5M | $24.2M | ||
| Q3 24 | $-6.7M | $8.4M | ||
| Q2 24 | $-10.1M | $-2.6M |
| Q1 26 | — | — | ||
| Q4 25 | $31.1M | $8.9M | ||
| Q3 25 | $28.0M | $9.8M | ||
| Q2 25 | $22.2M | $-9.5M | ||
| Q1 25 | $-13.6M | $-1.8M | ||
| Q4 24 | $-4.5M | $23.4M | ||
| Q3 24 | $-6.7M | $8.4M | ||
| Q2 24 | $-10.1M | $-2.6M |
| Q1 26 | — | — | ||
| Q4 25 | 53.9% | 10.9% | ||
| Q3 25 | 47.7% | 11.9% | ||
| Q2 25 | 35.6% | -11.7% | ||
| Q1 25 | -23.7% | -2.5% | ||
| Q4 24 | -9.6% | 31.5% | ||
| Q3 24 | -17.9% | 10.7% | ||
| Q2 24 | -23.1% | -3.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.1% | 1.1% | ||
| Q2 25 | 0.2% | 1.3% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.06× | ||
| Q3 25 | 52.05× | 0.77× | ||
| Q2 25 | 90.47× | -0.61× | ||
| Q1 25 | -2.22× | -0.20× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | — | 0.59× | ||
| Q2 24 | — | -0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
AMSF
Segment breakdown not available.
